Cosentyx (secukinumab) Please rate this page (bottom of page)

Share Button

This page contains a brief description that does not cover the medication. For more information read the review in for the respective drug.


The active substance is secukinumab which blocks IL-17 in the immune system and thus reduces rheumatic inflammation. Cosentyx is given as an injection under the skin (subcutaneously). The dose is 150-300mg subcutaneously monthly, often with more frequent dosing in the first weeks of treatment and depending on the disease being treated.


Cosentyx is not the first treatment choice


Side effects

Immunosuppressive therapy increases the risk of infection. More on side effects, precautions here (the Norwegian «Felleskatalogen»)


Patient information



This page has had 1 visits today

Please rate this page